Literature DB >> 3470110

Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion.

N Jaffe, R Keifer, R Robertson, A Cangir, A Wang.   

Abstract

Sequential corrected creatinine clearance (CCC) evaluations were obtained in 30 patients treated with intra-arterial and/or intravenous cis-diamminedichloroplatinum-II (CDP). The dose was 150 mg/M2 administered with mannitol diuresis at 2 to 3 weekly intervals. Four hundred fifty-three courses were administered (range, 6-18) over 18 months. Patients also were treated with 283 courses of high-dose methotrexate (MTX) and citrovorum factor "rescue" which were interposed between treatments. Deleterious effects of cumulative courses of CDP manifested as progressive reductions in CCC and delayed excretion of serum MTX. Severe MTX toxicity was aborted by augmenting the fluid intake and prolonging citrovorum factor rescue when elevated levels of serum MTX were detected. The first indication of renal induced CDP toxicity occurred with a cumulative dose of 450 mg/M2. At the termination of treatment (cumulative CDP dose over 1050 mg/M2) renal impairment still was present.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470110     DOI: 10.1002/1097-0142(19870501)59:9<1577::aid-cncr2820590908>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Genitourinary long-term outcomes for childhood cancer survivors.

Authors:  Margarett Shnorhavorian; Debra L Friedman; Martin A Koyle
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

3.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 4.  Cytostatics--induced tubular toxicity.

Authors:  M Brandis; K von der Hardt; R B Zimmerhackl; M Mohrmann; J Leititis
Journal:  Clin Investig       Date:  1993-10

5.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.

Authors:  J D Borsi; D Schuler; P J Moe
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Cisplatin therapy in infants: short and long-term morbidity.

Authors:  P R Brock; E C Yeomans; S C Bellman; J Pritchard
Journal:  Br J Cancer Suppl       Date:  1992-08

8.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

9.  Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma.

Authors:  K O Misaka; Yukio Suga; Yukiko Staub; Atsumi Tsubata; Tsutomu Shimada; Yoshimichi Sai; Ryo Matsushita
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 10.  Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.

Authors:  Marc Garcia-Moure; Naiara Martinez-Vélez; Ana Patiño-García; Marta M Alonso
Journal:  J Bone Oncol       Date:  2016-12-14       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.